Vivani Medical (NASDAQ:VANI) Stock: Insider Donald Dwyer Acquires 20,000 Shares

Vivani Medical, Inc. (NASDAQ:VANI) insider Donald Dwyer bought 20,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were acquired at an average cost of $0.98 per share, for a total transaction of $19,600.00. Following the completion of the transaction, the insider owned 75,000 shares of the company’s stock, valued at approximately $73,500. The trade was a 36.36% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vivani Medical Trading Up 2.7%

NASDAQ VANI traded up $0.03 during mid-day trading on Friday, reaching $1.01. 368,707 shares of the company’s stock traded hands, compared to its average volume of 256,490. Vivani Medical, Inc. has a 1-year low of $0.80 and a 1-year high of $1.66. The company has a fifty day simple moving average of $1.18 and a 200-day simple moving average of $1.24. The company has a market cap of $91.10 million, a price-to-earnings ratio of -3.16 and a beta of 2.51.

Vivani Medical (NASDAQ:VANI) last released its earnings results on Wednesday, November 11th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01.

Wall Street Analyst Weigh In

A number of research analysts have commented on VANI shares. Wall Street Zen downgraded shares of Vivani Medical from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, October 2nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $3.75.

Vivani Medical Company Profile

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.